Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

Jules Bordet Institute, Brussels, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:4City/State/Province:Brussels
Treatments:Chemotherapy, Biologic therapyHospital:Jules Bordet Institute
Drugs:Journal:Link
Date:Dec 2013

Description:

Patients:
This phase 2 study involved female, previously treated, HER2+, locally advanced/metastatic breast cancer patients who were divided into two separate treatment groups. Group A had 117 patients with a median age of 52 years. Group B had 116 patients with a median age of 56 years.

Treatment:
Patients in group A were treated with the biologic therapy agent neratinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Patients in group B received chemotherapy with capecitabine and biologic therapy with lapatinib, which is a tyrosine kinase inhibitor that interferes with tumor growth.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 diarrhea, nausea, and vomiting.

The most severe toxicities were of grade 4 and included grade 3-4 hand-foot syndrome (skin reaction), diarrhea, and stomatitis (inflammation of the GI tract).

Results:
The median overall survival times for groups A and B were 19.7 and 23.6 months, respectively.

Support:
This study was supported by Wyeth Research.

Correspondence: Dr. Ahmad Awada; email: [email protected]



Back